Evaluation of Hemodialysis Effect on Pharmacokinetics of Meropenem/Vaborbactam in End-Stage Renal Disease Patients Using Modeling and Simulation.

Journal of Clinical Pharmacology
Luning ZhuangYaning Wang

Abstract

The objectives of this study were to evaluate the effect of hemodialysis (HD) on the pharmacokinetics (PK) of meropenem/vaborbactam, an approved beta-lactam/beta-lactamase inhibitor combination, and provide the rationale for the recommended timing of meropenem/vaborbactam administration relative to HD in end-stage renal disease (ESRD) patients. Population PK models were developed separately for meropenem and vaborbactam in subjects with normal renal function and different degrees of renal impairment, including those receiving HD. Simulations were performed to evaluate the exposure of meropenem and vaborbactam in ESRD patients who received a fixed dose of 0.5 g/0.5 g meropenem/vaborbactam every 12 hours as a 3-hour intravenous infusion under various drug administration schedules relative to HD. The probability of target attainment (PTA) analyses were conducted with pharmacokinetic/pharmacodynamic (PK/PD) targets of meropenem and vaborbactam. Simulations showed that HD reduces the accumulation of vaborbactam, but the exposure of vaborbactam is still above the PK/PD target regardless of whether meropenem/vaborbactam is administered predialysis or postdialysis. For meropenem, drug infusion completed right prior to initiation of HD ...Continue Reading

References

Jan 5, 2002·Journal of Pharmacokinetics and Pharmacodynamics·S L Beal
Jul 2, 2003·Drugs·Nelson LeeCyrus R Kumana
Jan 24, 2004·The Journal of Pharmacy and Pharmacology·T ErikssonG A Kaysen
Sep 9, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·David P Nicolau
Jan 26, 2013·Annals of the New York Academy of Sciences·David M Shlaes
Sep 11, 2013·Antimicrobial Agents and Chemotherapy·Angela S LooMarc H Scheetz
Jan 22, 2017·CPT: Pharmacometrics & Systems Pharmacology·B WangL K Roskos
Jan 10, 2018·Antimicrobial Agents and Chemotherapy·Christopher M RubinoDavid C Griffith
Nov 7, 2018·Antimicrobial Agents and Chemotherapy·David C GriffithMichael N Dudley

❮ Previous
Next ❯

Citations

Jul 3, 2021·Antibiotics·Giacomo LuciAntonello Di Paolo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Beta-lactamase Inhibitors

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Beta-lactamase Inhibitors (ASM)

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.